Bristow Endeavor Healthcare, LLC v. Blue Cross & Blue Shield Ass'n

691 F. App'x 515
CourtCourt of Appeals for the Tenth Circuit
DecidedMay 31, 2017
Docket16-5149
StatusUnpublished
Cited by9 cases

This text of 691 F. App'x 515 (Bristow Endeavor Healthcare, LLC v. Blue Cross & Blue Shield Ass'n) is published on Counsel Stack Legal Research, covering Court of Appeals for the Tenth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Bristow Endeavor Healthcare, LLC v. Blue Cross & Blue Shield Ass'n, 691 F. App'x 515 (10th Cir. 2017).

Opinion

ORDER AND JUDGMENT *

Carlos F. Lucero, Circuit Judge

Bristow Endeavor Healthcare, LLC, (“Bristow”) appeals a district court order granting motions to dismiss filed by Blue Cross and Blue Shield Association (“BCBSA”) and Health Care Service Corporation (“HCSC”). Exercising jurisdiction under 28 U.S.C. § 1291, we affirm.

I

Bristow is a healthcare company that operates three facilities in northeast Oklahoma: Bristow Medical Center (“BMC”), Cimarron Healthcare Center (“Cimar-ron”), and the Center for Orthopaedic Reconstruction and Excellence (“CORE”). BCBSA is a federation of independent Blue Cross and Blue Shield companies, including HCSC, which does business as Blue Cross Blue Shield of Oklahoma. Bris-tow alleges that HCSC exercises market dominance in. the northeast Oklahoma market, with at least 64% of the market for health insurers.

BMC is an in-network provider with HCSC. In-network providers receive contractually set payments for healthcare services offered to individuals with HCSC plans. In 2013, Bristow requested that Ci-marron be added to the existing in-network provider agreement with BMC. Following negotiations, the parties agreed to add Cimarron and adopt a blended rate for reimbursement payments to both facilities. In March 2014, Bristow and HCSC executed a BlueTraditional Network Participating Hospital Agreement (the “Provider Agreement”), which applied to. both BMC and Cimarron. Bristow states that it had an “implicit understanding” that the Provider Agreement would also include all future Bristow entities. However, the Provider Agreement specifically states that additional entities may be added only with the consent of HCSC.

In March 2015, Bristow requested that HCSC add Bristow’s new facility, CORE, to the Provider Agreement. HCSC sent Bristow a credentialing application for CORE. After requesting additional information, HCSC informed Bristow that it would not agree to add CORE to the Provider Agreement, but it offered to enter into a separate agreement with the facility. The parties continued discussions through December 2015 but did not reach an agreement.

Bristow alleges that HCSC refused to grant CORE in-network status as a result of a conspiracy to restrain trade with Hill-crest Healthcare System (“Hillcrest”) and Ardent Health Services (“Ardent”). Hill-crest operates several healthcare facilities in northeast Oklahoma and is Bristow’s largest competitor. Ardent owns Hillcrest. Bristow alleges that Hillcrest and its affiliated companies exercise markét dominance in the northeast Oklahoma market. But Bristow merely characterizes Hill-crest’s market share as “high” without any particular factual allegations. Bristow also alleges that HCSC reimburses Hillcrest at higher rates than those offered to BMC *518 and Cimarron. It claims that the purpose of the conspiracy is to prevent CORE from fully competing with Hillcrest in the northeast Oklahoma healthcare market, thereby allowing Hillcrest to maintain and expand its market share in that area.

In support of its conspiracy claim, Bris-tow alleges that representatives of Tulsa Spine & Specialty. Hospital (“Tulsa Spine”), a Hillcrest facility, met with representatives of Hillcrest and Ardent on a weekly basis between 2011 and 2015 to “discuss affairs, including CORE.” In the summer of 2014, Tulsa Spine hired a private investigator to look into individuals involved in the start-up of CORE. Bristow further alleges, on information and belief, that HCSC participated in some of these meetings and related phone calls, during which it discussed ways to prevent CORE from becoming an in-network provider.

Bristow provides two particular allegations in support of its claim of conspiracy. First, it alleges, on information and belief, that a “representative of Blue Cross Blue Shield” 1 told a Bristow representative CORE was being denied a contract for “CORE’S own protection" and that “if Hill-crest tried to open a facility in Bristow, we [Blue Cross Blue Shield] would ‘protect you [Bristow].”’ 2 Second, Bristow claims that sometime between December 2014 and January 2015, Eddie Gwock, an Ardent representative, told Tulsa Spine that “he could leverage his relationship with Blue Cross Blue Shield to keep CORE out of the network.” Gwock “also reported that he spoke with Blue Cross Blue Shield, and in connection with the ‘strategic initiative’ between Blue Cross Blue Shield, [Ardent, and Hillcrest], Blue Cross Blue Shield would be able to keep CORE out of network.”

Bristow filed suit against HCSC, BCBSA, Ardent, Hillcrest, and related entities advancing four claims: (1) violation of § 1 of the Sherman Act, 15 U.S.C § 1; (2) state law conspiracy in violation of Okla. Stat. tit. 79, § 203(A); (3) attempt to monopolize in violation of Okla. Stat. tit. 79, § 203(B); and (4) tortious interference with business relations. The district court granted motions to dismiss filed by HCSC and BCBSA. Bristow then voluntarily dismissed its claims against the remaining defendants with prejudice and filed a timely appeal.

II

We review a Fed. R. Civ. P, 12(b)(6) dismissal de novo, accepting as true all well-pled factual allegations in the complaint and viewing them in the light most favorable to the plaintiff. Smith v. United States, 561 F.3d 1090, 1098 (10th Cir. 2009). “To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible on its face.’” Ashcroft v. Iqbal, 556 U.S. 662, 678, 129 S.Ct. 1937, 173 L.Ed.2d 868 (2009) (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)). A claim is facially plausible if the plaintiff has pled “factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Id. A complaint that “tenders naked assertions devoid of further factual enhancement” is insufficient. Id. (quotations and alteration omitted). Further, if a complaint alleges “facts that are merely consistent with a defendant’s liability, it stops short of the line between *519 possibility and plausibility of entitlement to relief.” Id. (quotations omitted).

A

Section 1 of the Sherman Act makes it illegal to engage in a “conspiracy[ j in restraint of trade or commerce.” 15 U.S.C. § 1. The Act “does not prohibit [all] unreasonable restraints of trade ... but only restraints effected by a contract, combination, or conspiracy.” Copperweld Corp. v. Indep.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
691 F. App'x 515, Counsel Stack Legal Research, https://law.counselstack.com/opinion/bristow-endeavor-healthcare-llc-v-blue-cross-blue-shield-assn-ca10-2017.